S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
NASDAQ:NBIX

Neurocrine Biosciences (NBIX) Stock Forecast, Price & News

$92.32
+1.13 (+1.24%)
(As of 06/2/2023 ET)
Compare
Today's Range
$90.54
$92.53
50-Day Range
$89.53
$104.87
52-Week Range
$88.38
$129.29
Volume
422,520 shs
Average Volume
713,093 shs
Market Capitalization
$9.01 billion
P/E Ratio
153.87
Dividend Yield
N/A
Price Target
$125.21

Neurocrine Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
35.6% Upside
$125.21 Price Target
Short Interest
Bearish
2.86% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.96mentions of Neurocrine Biosciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$3.84 M Sold Last Quarter
Proj. Earnings Growth
156.04%
From $1.82 to $4.66 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.64 out of 5 stars

Medical Sector

82nd out of 983 stocks

Biological Products, Except Diagnostic Industry

12th out of 164 stocks


NBIX stock logo

About Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops, and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Stock News Headlines

Famous Wall Street Crash System Flashes RED
Hundreds of banks, hedge funds, and brokerages have paid $5,000 a month to access these alerts. Because when this system flashes on U.S. stocks, huge gains – and losses – can follow.
Introducing MarketBeat All Access
Get real-time financial news and market data with MarketBeat All Access. Monitor your portfolio and the markets. Access our top stock picks, unbeatable research tools, best-in-class stock screeners, and proprietary research reports.
Neurocrine (NBIX) Gets a Hold from Mizuho Securities
See More Headlines

NBIX Price History

NBIX Company Calendar

Last Earnings
2/06/2023
Today
6/04/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NBIX
CUSIP
64125C10
Employees
1,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$125.21
High Stock Price Forecast
$150.00
Low Stock Price Forecast
$95.00
Forecasted Upside/Downside
+35.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
17 Analysts

Profitability

Net Income
$154.50 million
Pretax Margin
5.58%

Debt

Sales & Book Value

Annual Sales
$1.49 billion
Cash Flow
$1.80 per share
Book Value
$17.26 per share

Miscellaneous

Free Float
93,282,000
Market Cap
$9.01 billion
Optionable
Optionable
Beta
0.48

Key Executives

  • Kevin Charles GormanKevin Charles Gorman
    Chief Executive Officer & Director
  • Bill Wilson
    Vice President-Information Technology & Operations
  • Matthew C. Abernethy
    Chief Financial Officer
  • Dimitri E. GrigoriadisDimitri E. Grigoriadis
    Chief Research Officer
  • Eiry W. RobertsEiry W. Roberts
    Chief Medical Officer













NBIX Stock - Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 5 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NBIX shares.
View NBIX analyst ratings
or view top-rated stocks.

What is Neurocrine Biosciences' stock price forecast for 2023?

17 Wall Street research analysts have issued twelve-month price targets for Neurocrine Biosciences' stock. Their NBIX share price forecasts range from $95.00 to $150.00. On average, they predict the company's share price to reach $125.21 in the next year. This suggests a possible upside of 35.6% from the stock's current price.
View analysts price targets for NBIX
or view top-rated stocks among Wall Street analysts.

How have NBIX shares performed in 2023?

Neurocrine Biosciences' stock was trading at $119.44 at the beginning of 2023. Since then, NBIX shares have decreased by 22.7% and is now trading at $92.32.
View the best growth stocks for 2023 here
.

When is Neurocrine Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our NBIX earnings forecast
.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its quarterly earnings data on Monday, February, 6th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.15 by $0.09. The firm earned $412 million during the quarter, compared to analysts' expectations of $408.96 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 4.03% and a net margin of 4.00%. Neurocrine Biosciences's revenue for the quarter was up 32.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.08) earnings per share.

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.80%), State Street Corp (3.89%), Renaissance Technologies LLC (2.00%), Bank of New York Mellon Corp (1.69%), Armistice Capital LLC (1.63%) and Geode Capital Management LLC (1.47%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends
.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $92.32.

How much money does Neurocrine Biosciences make?

Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $9.01 billion and generates $1.49 billion in revenue each year. The company earns $154.50 million in net income (profit) each year or $0.60 on an earnings per share basis.

How many employees does Neurocrine Biosciences have?

The company employs 1,200 workers across the globe.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602.

This page (NASDAQ:NBIX) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -